and regulatory activities to support the planned new drug application (NDA) submission in early 2018" "Women in the trials had the option, after completion of the trial, to continue in an open-label safety extension study for an additional 12 months. Nearly 80% of patients elected to remain in the open-label portion of the study, and all of these patients received bremelanotide."
Und, wie Cobra7 schon zitierte, höchst erfreulich: "we have more financial flexibility to invest in our newest products -- Intrarosa and bremelanotide" #1272 = Link = Quelle für die Zitate
|